A

Training cohort	TCGA-KIRC (n = 331)		High risk score (n = 166)		Low risk score (n = 165)	
Number of Patients	531		266		265	
T_Stage						
T1	160	(48.34%)	64	(38.55%)	96	(58.18%)
T2	42	(12.69%)	22	(13.25%)	20	(12.12%)
T3	120	(36.25%)	71	(42.77%)	49	(29.70%)
T4	9	(2.72%)	9	(5.42%)	0	(0.00%)
N_Stage						
N0	149	(45.02%)	73	(43.98%)	76	(46.06%)
N1	13	(3.93%)	7	(4.22%)	6	(3.64%)
NX	169	(51.06%)	86	(51.81%)	83	(50.30%)
M_Stage						
NA	1	(0.30%)	1	(0.60%)	0	(0.00%)
M0	262	(79.15%)	123	(74.10%)	139	(84.24%)
M1	51	(15.41%)	34	(20.48%)	17	(10.30%)
MX	17	(5.14%)	8	(4.82%)	9	(5.45%)
Stage						
NR	3	(0.91%)	2	(1.20%)	1	(0.61%)
Stage I	156	(47.13%)	62	(37.35%)	94	(56.97%)
Stage II	34	(10.27%)	16	(9.64%)	18	(10.91%)
Stage III	85	(25.68%)	50	(30.12%)	35	(21.21%)
Stage IV	53	(16.01%)	36	(21.69%)	17	(10.30%)
OS						
Mean	1340.29		1191.33		1490.15	
median	1218.00		1138.50		1314.00	
Age						
≤60	160	(48.34%)	81	(48.80%)	79	(47.88%)
>60	171	(51.66%)	85	(51.20%)	86	(52.12%)
Gender						
Female	114	(34.44%)	49	(29.52%)	65	(39.39%)
Male	217	(65.56%)	117	(70.48%)	100	(60.61%)

B

Training cohort	TCGA-KIRC (n = 331)		High risk score (n = 166)		Low risk score (n = 165)	
Number of Patients	531		266		265	
T_Stage						
T1	160	(48.34%)	64	(38.55%)	96	(58.18%)
T2	42	(12.69%)	22	(13.25%)	20	(12.12%)
T3	120	(36.25%)	71	(42.77%)	49	(29.70%)
T4	9	(2.72%)	9	(5.42%)	0	(0.00%)
N_Stage						
N0	149	(45.02%)	73	(43.98%)	76	(46.06%)
N1	13	(3.93%)	7	(4.22%)	6	(3.64%)
NX	169	(51.06%)	86	(51.81%)	83	(50.30%)
M_Stage						
NA	1	(0.30%)	1	(0.60%)	0	(0.00%)
M0	262	(79.15%)	123	(74.10%)	139	(84.24%)
M1	51	(15.41%)	34	(20.48%)	17	(10.30%)
MX	17	(5.14%)	8	(4.82%)	9	(5.45%)
Stage						
NR	3	(0.91%)	2	(1.20%)	1	(0.61%)
Stage I	156	(47.13%)	62	(37.35%)	94	(56.97%)
Stage II	34	(10.27%)	16	(9.64%)	18	(10.91%)
Stage III	85	(25.68%)	50	(30.12%)	35	(21.21%)
Stage IV	53	(16.01%)	36	(21.69%)	17	(10.30%)
OS						
Mean	1340.29		1191.33		1490.15	
median	1218.00		1138.50		1314.00	
Age						
≤60	160	(48.34%)	81	(48.80%)	79	(47.88%)
>60	171	(51.66%)	85	(51.20%)	86	(52.12%)
Gender						
Female	114	(34.44%)	49	(29.52%)	65	(39.39%)
Male	217	(65.56%)	117	(70.48%)	100	(60.61%)